Skandinaviska Enskilda Banken Ab (Publ) Editas Medicine, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$9.99 - $21.35 $48,701 - $104,081	-4,875 Reduced 10.47%	41,687 $493,000
Q1 2022 May 11, 2022	SELL	$14.08 - $27.63 $215,452 - $422,794	-15,302 Reduced 24.73%	46,562 $885,000
Q3 2021 Nov 10, 2021	BUY	$39.27 - $72.94 $814,067 - $1.51 Million	20,730 Added 50.4%	61,864 $2.54 Million
Q2 2021 Aug 10, 2021	BUY	$31.29 - $56.64 $36,984 - $66,948	1,182 Added 2.96%	41,134 $2.33 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $894,388 - $2.04 Million	22,523 Added 129.23%	39,952 $1.68 Million
Q4 2020 Feb 11, 2021	SELL	$27.07 - $84.35 $5,224 - $16,279	-193 Reduced 1.1%	17,429 $1.22 Million
Q3 2020 Nov 12, 2020	BUY	$28.06 - $37.16 $483,305 - $640,043	17,224 Added 4327.64%	17,622 $494,000
Q2 2020 Aug 13, 2020	BUY	$18.5 - $34.34 $7,363 - $13,667	398 New	398 $12,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.